Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06378632 · ClinicalTrials.gov registry record

AN International, Observational, Blinded Study TO Assess THE Performance OF THE Cordio Hearo System

A clinical trial of Heart Failure, sponsored by Cordio Medical.

Recruiting
Registry status
500
Enrollment target
20
Study locations

NCT06378632: Recruiting study of Heart Failure, sponsored by Cordio Medical.

NCT06378632 is a study of Heart Failure that is actively recruiting participants, run by Cordio Medical. The registered enrollment target is 500 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06378632, a study of Heart Failure, is actively recruiting participants, sponsored by Cordio Medical.

RECRUITING
Registry status
500 participants
Enrollment target
20
Study locations

Study Summary

Study Design: This is an international, multicenter, observational, non-interventional, prospective, blinded, single-arm, two-period study, to collect patient utterances that will be retrospectively analyzed to determine the sensitivity and UPNR of the HearO system.

Primary Outcome

Until the end of the study, each participant will be assigned to one of the following event outcomes: 1. Having at least one protocol-defined Heart Failure Event (HFE) in the CORE period 2. Having no Heart Failure Event (HFE) during the entire CORE period

Conditions Studied

Interventions

  • DEVICE Hearo App

Study Locations (20)

Florida

  • Nature Coast Clinical Research - Crystal River
  • Jacksonville Center for Clinical Research - Jacksonville
  • Amavita Clinical Research - Miami
  • Advance Medical Research Services Corp (AMRS) - Miami
  • Baptist Health (Miami Cardiac & Vascular Institute) - Miami
  • Comprehensive Medical & Research Center - Plantation
  • St. Johns Center for Clinical Research - Saint Augustine
  • Tampa General Hospital - Tampa

California

  • UC San Diego Health - La Jolla
  • VA Loma Linda Healthcare System - Loma Linda
  • VA San Diego - San Diego
  • University of California, San Francisco - San Francisco
  • Kaiser Permanente San Francisco - San Francisco

Illinois

  • University of Chicago - Chicago
  • Advocate Illinois Masonic Medical Center - Chicago
  • Advocate Illinois Masonic Health Center - Downers Grove
  • Midwest Cardiovascular Center - Naperville

Alabama

  • Eastern Shore Research Institute - Fairhope

Georgia

  • West Georgia Cardiology - Carrollton

Kansas

  • Robert J. Dole VA Medical Center - Wichita

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2022-02-11
Est. Completion 2025-07-15
Cordio Medical

2 total trials

What NCT06378632 shows while recruiting

NCT06378632 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (76% lower).

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Hearo App is the first listed.

NCT06378632 names 20 study sites across 6 states, led by Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT06378632 about?

NCT06378632 is a clinical study titled "AN International, Observational, Blinded Study TO Assess THE Performance OF THE Cordio Hearo System". Study Design: This is an international, multicenter, observational, non-interventional, prospective, blinded, single-arm, two-period study, to collect patient utterances that will be retrospectively analyzed to determine the sensitivity and UPNR of the HearO system.

What is the current status of trial NCT06378632?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2022-02-11. Estimated completion is 2025-07-15.

What conditions does trial NCT06378632 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT06378632?

The interventions under investigation include: Hearo App (DEVICE).

Who is sponsoring clinical trial NCT06378632?

This trial is sponsored by Cordio Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06378632 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06378632's enrollment target sits among peer trials

500 101st of 397 higher than 294 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06378632, the US trial registry maintained by the National Library of Medicine. NCT06378632 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.